Genetic inhibition of each lipid-modifying target was associated with lower CAD risk (HMGCR: 0.66 per 1 SD reduction in LDL-C, 95% CI 0.54 to 0.81 and PCSK9: 0.55, 95% CI 0.34 to 0.90). The gene discussed is PCSK9; the disease is coronary artery disorder.